Is SMMT or SPRC more undervalued in 2026?

CirclFi compares Summit Therapeutics Inc. (SMMT) and SciSparc Ltd. (SPRC) using 13 institutional-grade valuation models. SMMT has a Quality of Company score of 4.4/10 while SPRC scores 1.7/10.

Which is a better buy — SMMT or SPRC?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do SMMT and SPRC valuations compare?

SMMT at $17.41 and SPRC at $10.55 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

SMMT vs SPRC Valuation Comparison 2026 — Intrinsic Value Analysis

SMMT

Biotechnology

Summit Therapeutics Inc.

Quality

4.4

out of 10

Value Trap

SAFE

Price

$17.41

Last close

Models

12/13

Active

SPRC

Biotechnology

SciSparc Ltd.

Quality

1.7

out of 10

Value Trap

—

Price

$10.55

Last close

Models

6/13

Active

Model-by-Model Comparison

Model	Type	SMMT Fair Value	SMMT Upside	SPRC Fair Value	SPRC Upside
Bayesian DCF	Intrinsic	$5.97	-65.7%	$2.79	-73.5%
Earnings Power Value	Intrinsic	$10.70	-51.5%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	—	—	$5.10	+24.5%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for SMMT vs SPRC — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

SMMT vs SPRC — Which Stock Is More Undervalued?

SMMT scores higher with a 4.4/10 quality rating vs SPRC's 1.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Summit Therapeutics Inc. (SMMT) and SciSparc Ltd. (SPRC) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

SMMT currently trades at $17.41 with a QOC of 4.4/10, while SPRC trades at $10.55 with a QOC of 1.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).